Daxxify's marketing promise—up to 6 months of effect versus Botox's standard 12 weeks—has reshaped competitive positioning in the toxin space. But the clinical reality is more nuanced than the headline suggests. Real-world efficacy depends on patient metabolism, injection technique, and unit dosing; some patients see meaningful extension, others see minimal difference.
Injectables
Daxxify Duration Claims vs. Reality
What the data actually shows about Revance's longer-lasting neuromodulator.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Real-world efficacy depends on patient metabolism and injection technique—not all patients see the promised 6-month extension.
The mechanism—peptide-stabilized botulinum toxin—is sound, but onset is slower (7–10 days versus 3–5), and the per-unit cost premium remains steep relative to established products. For practices, the decision hinges on patient willingness to pay for convenience (fewer appointments) and whether your rebate structure with Allergan or Galderma makes a switch economically viable. Daxxify adoption has been steady but not explosive, suggesting many owners view it as a niche option rather than a category disruptor.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.